Seroba.’s Post

Now this is interesting news: https://lnkd.in/g6_8za3T... Swiss Pharmacan announced the full results of Phase II double-blind, placebo-controlled clinical trial for its anti-inflammatory treatment ArtemiC on persons diagnosed with COVID-19. ArtemiC met all the Phase II primary and secondary endpoints and demonstrated to improve the clinical recovery of COVID-19 patients. The results of the clinical trial on ArtemiC involving 50 patients show that the treatment statistically significantly improved the clinical recovery of COVID-19 patients in comparison with the Placebo Group. The results deliver a full safety and efficacy profile, demonstrating to improve and expedite the clinical recovery in moderate COVID-19 patients, with no drug-related adverse events. None of the patients supported by ArtemiC required additional oxygen, mechanical ventilation or intensive care, compared to 23.4% in the placebo group requiring further assistance. The trial was completed on 50 COVID-19 infected patients across 3 independent hospital sites in Israel and met all the FDA requirements for a COVID-19 study. These results now open potential market opportunities for ArtemiC to a wide range of diseases related to cytokine storm such as influenza, autoimmune diseases, inflammatory GI diseases and chemotherapy patients. Following the successful Phase II results, a Phase III clinical trial is planned for the first half of 2021. The Phase III trial is anticipated to be an international multicentre study to encompass a wide range of inflammatory indications for the use of ArtemiC as a treatment. Swiss Pharmacan has partnered with the Australian MGC Pharma for the clinical trial. US-based Relay Medical has acquired the exclusive North American rights for the manufacturing and sales of several products of Swiss Pharmacan.

How to be tenacious.

🚀 Exciting News in the Biotech Sphere! 🚀 In an impressive stride for cancer therapy innovation, Clasp Therapeutics announced its launch this Wednesday, boasting a formidable $150 million in Series A financing. Situated in the key biotech hubs of Cambridge, Massachusetts, and Rockville, Maryland, Clasp Therapeutics is embarking on a mission to revolutionize the landscape of cancer treatment. This startup is not just another name in the vast sea of biotech. With heavyweight investors like Novo Holdings, Third Rock Ventures, Catalio Capital Management, and support from the American Cancer Society’s philanthropic fund among others, Clasp stands out with its ambition to develop a portfolio of next-generation immunotherapies. These therapies are designed to be both personalized and readily available, targeting the most challenging tumors with precision and efficacy. At the helm of Clasp Therapeutics is CEO Robert Ross, a figure well-known in the oncology field for his leadership at Surface Oncology Inc. before its acquisition and his impactful work at bluebird bio. Under his guidance, Clasp is delving into the potential of T cell engagers (TCEs), an emerging and promising approach in cancer treatment. Unlike conventional methods, Clasp’s TCEs aim to minimize off-target effects by targeting peptides presented by specialized HLA molecules on cancer cells, thus enabling a more precise attack on tumors. This innovative approach offers the dual benefits of personalized therapy's efficacy with the convenience and quicker treatment times of off-the-shelf options. It's a game-changer in oncology, promising to bring Clasp’s pioneering candidates to the clinic soon for early proof-of-concept data. As the biotech landscape continues to evolve, Clasp Therapeutics is undoubtedly a company to watch, heralding a new era of cancer treatment with its groundbreaking work. #Biotech #Innovation #CancerTherapy #ClaspTherapeutics #Immunotherapy

Empower your legal journey with a unique story of resilience and entrepreneurship!  Join the conversation on crafting a compelling narrative and overcoming challenges. Watch the inspiring Q&A session here: https://lnkd.in/gQiShA4a #legalcareer #entrepreneurship #resilience

💶 🚨 SciRhom has secured a EUR 63 Million Series A financing to accelerate iRhom2-targeting therapies in autoimmune diseases. ⬇ The financing enables us to shift gears and accelerate our novel and potentially groundbreaking therapeutic strategy toward clinical proof-of-concept and beyond to reach patients in need of better autoimmune treatments. SciRhom aims to push the boundaries in autoimmune medicine by addressing TACE/ADAM17, a master switch for various autoimmune disease-relevant signaling pathways, via iRhom2. The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors including HTGF | High-Tech Gründerfonds and the US-based PhiFund Ventures. We are excited to have attracted such a high-caliber international consortium of investors and appreciate our existing shareholders backing SciRhom in this crucial period of its development. In conjunction with this investment, we are excited to welcome Olivier Litzka, Peter Neubeck, Georgina Askeland, PhD, Dr. Fei Tian, and Varun Gupta to SciRhom’s Board of Directors and look forward to collaborating with them. Stay tuned and follow us here on LinkedIn to learn more about our novel approach as we progress toward initiation of a first clinical study in H2 2024. #venturecapital #financing #funding #fundingalert #SeriesA #iRhom2 #ADAM17 #TACE #autoimmune #IBD #RA #drugdiscovery #antibodyresearch #munichbiotech

Thanks, Illumina, for the support! We at Akrivia are committed to bringing the first-of-its-kind multi-parametric (Multi-Omics) approach-based diagnostic tests that combine genomic, transcriptomic, and immune signals to design optimal treatment plans tailored to each cancer patient based on a comprehensive understanding of their tumour biology. #PrecisionOncology #IlluminaGrant #AkriviaBiosciences #MultiOmics #BreastCancer #PrecisionMedicine

Bayer has secured significant victories in Roundup cancer trials in recent months. Read more of the latest 2024 developments in our recent blog post to prepare your legal team: https://bit.ly/3xbZsAx #RoundUp #RoundUpLawsuit

Embark on a transformative legal journey fueled by resilience and entrepreneurship! Dive into my unique story of crafting a compelling narrative and conquering challenges. Watch the inspiring Q&A session now to ignite your own path to success. Watch here: https://lnkd.in/gdgdSH32 #LegalJourney #Resilience #Entrepreneurship

You can find some of my thoughts on that all-important Client-CDMO relationship in the article below. Surely that makes it worth a download ! #genetherapy #ATMPmanufacturing #team

Featured in today’s BiotechTV interview with Brad Loncar, our CEO Mark Velleca discussed Black Diamond’s MasterKey approach to precision #oncology with our two clinical-stage programs—BDTX-1535 and BDTX-4933—and the evolving #EGFR mutational landscape. "We realize that there’s upwards of fifty EGFR mutations that can all cause non-small cell lung cancer. This is where MasterKey comes in... nearly all oncogenic mutations of the EGFR cause the receptor to form a conformation that can be uniquely drugged by [BDTX-]1535.” Watch the interview below! #NSCLC